etoposide has been researched along with Adverse Drug Event in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 14 (46.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Xia, D; Xu, X; Yang, W; Zhang, Y | 1 |
| Duty, AM; Goldman, JL; Kelley, KL; Miles, N; Suppes, SL; Tillman, EM | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Baran, A; Barr, PM; Casulo, C; David, RJ; Friedberg, JW; Loh, KP; Reagan, PM | 1 |
| Hamanaka, K; Hyogotani, A; Koizumi, T; Koyama, T; Matsuoka, S; Sekiguchi, N; Takeda, T; Yamada, K | 1 |
| Biasoni, D; Catanzaro, M; Farè, E; Giannatempo, P; Gianni, AM; Mariani, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Pizzocaro, G; Raggi, D; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Cheng, Y; Feng, J; Han, B; Hao, X; Hou, M; Hu, C; Li, W; Liu, X; Liu, Y; Luo, X; Qin, S; Sun, Y; Wan, H; Wang, J; Xia, Z; Xiu, Q; Zhang, H; Zhang, L; Zhu, Y | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Han, XH; He, XH; Li, B; Liu, P; Shi, YK; Yang, JL; Yang, S; Zhang, CG; Zhou, SY | 1 |
| Cozza, R; De Ioris, MA; De Lurentis, C; De Sio, L; Fidani, P; Ilari, I; Jenkner, A; Milano, GM; Pessolano, R | 1 |
| Arceci, RJ; Bernstein, M; Buck, S; Chang, MN; Dahl, GV; Kshirsagar, S; Lacayo, NJ; Lum, BL; O'Brien, MM; Ravindranath, Y; Sikic, BI; Weinstein, H | 1 |
| Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A | 1 |
| Agarwala, S; Bhatnagar, V; Garg, R | 1 |
| Straus, DJ | 1 |
| Balis, F; Bates, S; Cole, D; Egorin, MJ; Flynn, BM; Fojo, T; Knutsen, T; Langham, G; Rao, VK; Ried, T; Steinberg, SM; Wangsa, D | 1 |
| Craft, A; Juergens, C; Juergens, H; Lewis, I; Michon, J; Oberlin, O; Paulussen, M; Weston, C; Whelan, J; Zoubek, A | 1 |
| Kantidze, OL; Razin, SV | 1 |
| Chen, YH; Hu, DN; Kuo, HK; Wu, PC; Wu, YC; Yang, PM | 1 |
| de Wit, R | 1 |
| Cheerva, AC; Gross, TG; Kadota, RP; Levine, JE; Ozkaynak, MF; Richards, MK; Rozans, MK; Sahdev, I; Shaw, PJ | 1 |
| Azuma, H; Inamoto, T; Katsuoka, Y; Kiyama, S; Kotake, Y; Nishimura, Y; Sakamoto, T; Segawa, N; Takahara, K; Ubai, T | 1 |
| Harvell, JD; Hashem, C; White, WL; Williford, PL | 1 |
| Abboud, CN; Constine, LS; DiPersio, JF; Duerst, RE; Horan, JT; Liesveld, JL; Passarell, JA; Raubertas, RF; Senf, ES; Zwetsch, LM | 1 |
| Cook, AM; Dzik-Jurasz, AS; Huddart, RA; Norman, A; Padhani, AR | 1 |
2 review(s) available for etoposide and Adverse Drug Event
| Article | Year |
|---|---|
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
5 trial(s) available for etoposide and Adverse Drug Event
| Article | Year |
|---|---|
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2016 |
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Cyclosporins; Drug Resistance, Multiple; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Young Adult | 2010 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult | 2011 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Kidney Neoplasms; Melphalan; Neoplasms; Neuroblastoma; Pilot Projects; Recurrence; Risk Factors; Sarcoma; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Wilms Tumor | 2008 |
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Etoposide; Graft Survival; Graft vs Host Disease; Humans; Infant; Leukemia; Myeloablative Agonists; Nuclear Family; Recurrence; Stomatitis; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
23 other study(ies) available for etoposide and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2021 |
Risks and mitigation strategies to prevent etoposide infusion-related reactions in children.
Topics: Antineoplastic Agents; Child; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Infusions, Intravenous; Neoplasms; Risk Factors | 2021 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Registries; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2018 |
Development of angiosarcoma in a mediastinal non-seminomatous germ cell tumor that exhibited growing teratoma syndrome during chemotherapy.
Topics: Adult; Biomarkers, Tumor; Bleomycin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Hemangiosarcoma; Hemorrhage; Humans; Male; Mediastinal Neoplasms; Neoplasms, Germ Cell and Embryonal; Teratoma; Testicular Neoplasms; Thoracic Surgical Procedures; Tomography, X-Ray Computed | 2019 |
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome | 2013 |
Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
Topics: Adolescent; Adult; Antigens, CD34; Child; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Male; Middle Aged; Neutropenia; Thrombocytopenia; Transplantation Conditioning; Treatment Outcome; Vomiting | 2009 |
Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kinetics; Male; Prognosis; Retrospective Studies; Sarcoma, Ewing; Thiotepa | 2010 |
Acute pancreatitis induced by ifosfamide therapy.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Ifosfamide; Pancreatitis; Recurrence; Wilms Tumor | 2010 |
HIV-associated lymphoma: promising new results, but with toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Infections; Lymphoma, AIDS-Related; Rituximab | 2005 |
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Topics: Animals; Area Under Curve; Azure Stains; Bone Marrow Cells; Chromosome Aberrations; Chromosome Painting; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Infusions, Intravenous; Macaca mulatta; Neutropenia; Paclitaxel; Thiotepa | 2005 |
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Clinical Trials as Topic; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Sarcoma, Ewing; Statistics, Nonparametric; Vincristine | 2006 |
Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements.
Topics: Antineoplastic Agents, Phytogenic; Chromatin Immunoprecipitation; Chromosome Aberrations; Chromosome Breakage; Core Binding Factor Alpha 2 Subunit; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type II; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Jurkat Cells; Leukemia; Neoplasms; Protein Binding; Rad52 DNA Repair and Recombination Protein; Recombination, Genetic; Topoisomerase II Inhibitors | 2007 |
Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Topics: Animals; Cell Survival; Cells, Cultured; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Etoposide; In Vitro Techniques; Injections; Male; Maximum Tolerated Dose; Pigment Epithelium of Eye; Rabbits; Topoisomerase II Inhibitors; Vitreoretinopathy, Proliferative; Vitreous Body | 2007 |
Refining the optimal chemotherapy regimen in good prognosis germ cell cancer: interpretation of the current body of knowledge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Neoplasms, Germ Cell and Embryonal; Prognosis; Quality of Life | 2007 |
Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Salvage Therapy; Survival Analysis | 2008 |
Grover's-like disease in the setting of bone marrow transplantation and autologous peripheral blood stem cell infusion.
Topics: Acantholysis; Adult; Bone Marrow Transplantation; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pemphigus | 1998 |
The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Etoposide; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Osteonecrosis; Prevalence; Surveys and Questionnaires; Testicular Neoplasms; Time Factors; United Kingdom; Vincristine | 2001 |